Free Essay

Glaxosmithkline

In: Business and Management

Submitted By slcmom911
Words 735
Pages 3
An analysis of GlaxoSmithKline and AIDS Drugs in South Africa

Maker of AIDS drugs, GlaxoSmithKline (GSK), is confronted with a question of ethics. Do they go the humanitarian route and provide drugs for AIDS victims in poor countries, or do they maintain that they’re a business and they’re here to make money? South Africa has the highest population of AIDS patients in the world. In the year 2000 roughly five million people (or 20%) of the population were infected with the disease. At this time some drugs to attack the virus had been developed. The problem was the cost of this treatment method (HAART) cost an estimated $10,000 to $15,000 a year. The average annual income in South Africa was approximately $2,000. What is a nation to do when a disease is spreading rapidly, killing off your people? The South African government decided to take matters into their own hands. If companies such as GSK wouldn’t make AIDS drugs affordable for their people they would get the drugs another way. In 1997 Nelson Mandela introduced the Medicines and Related Substances Control Amendment. With this amendment the South African government could import generic drugs. They saw this as the only way to get affordable AIDS drugs to help infected victims of the disease. In 1998 GSK and 41 other pharmaceutical companies filed a lawsuit against the South African government, brought on by the South African Medicines and Related Substances Control Amendment. The lawsuit argued that the amendment would allow the health minister to arbitrarily ignore patents on medications. And they were right. But is it a battle worth fighting? The merger that would become GlaxoSmithKline resulted in the largest pharmaceutical company in the world. They were also the largest AIDS drug producer in the world. AIDS drugs alone generated $2 billion in sales in 2000. South Africa represented only 1% of global sales for the company. GSK was a huge, profitable company, but with a pending lawsuit involving a question of ethics it made them a target for attacks from all angles. Many non-governmental organizations launched attacks and campaigns against GSK, demanding they remove the lawsuit against the South African government. Sixteen members from Globalise Resistance protested outside of GSK’s plant in Brentford, London. Oxfam International launched their “Cut the Cost” campaign to protest all pharmaceutical companies charging excessive prices in developing countries. Because it appeared that GSK was willing to sacrifice lives to make money NGO’s such as these and several others took a stand against the pharmaceutical powerhouse.
So was the 1% market worth the black eye it was given for claiming what they were entitled to? I don’t think so. While GSK had every right to be upset with the amendment introduced in 1997 which infringed upon their patents fighting it only proved to hinder more than help. It is my opinion that they would have been wise to recognize that a country such as South Africa won’t be able to pay the premium price for the drugs they so desperately need. By discounting them substantially or donating them all together they would be looked upon differently by the world, not as a pharmaceutical superpower that cares about nothing but the bottom line, but as a company that is genuinely concerned about the welfare of the world. Don’t get me wrong, I’m all for capitalism, but in a situation such as this one could do a lot of good for a company by giving a little and getting a lot back in return. I believe to be successful long term you have to look to the future, not just the “now.” The positive publicity and positive results from this type of action are immeasurable. The business generated could be tenfold the business they would have received selling drugs at a premium to South Africa.
In the end GSK ended up doing just that, they discounted their AIDS drugs to make them affordable to the people of South Africa and other underdeveloped nations. It could have been from the pressure of the NGO’s. It could be they felt they had more to gain in the long run by doing so. One thing is for certain, the damage had been done to GSK’s image. Had they not filed the lawsuit against the South African government, had they discounted the drugs initially, GlaxoSmithKline could have emerged as the humanitarian pharmaceutical superpower.

Similar Documents

Premium Essay

Glaxosmithkline Pestel Analysis

...GlaxoSmithKline PESTEL Analysis. The level of implementation of GlaxoSmithKline (GSK) marketing strategy is subject to a range of external and internal factors that shape overall marketing environment for the business. PESTEL strategic analytical tool can be used to study the impacts of external factors to the business where the abbreviation stands for political, economical, social, technological, ecological, and legal factors. Political factors affecting the implementation of GSK marketing strategy include possible changes in international trade regulation and competitive regulation likely to be introduced by the governments of China and India. Economic factors impacting GSK marketing strategy include high rate of economic growth in China and India. Moreover, current economic uncertainties associated with European markets might have negative implications on the marketing strategy Social factors with potential implications on GSK marketing strategy are changes in consumer lifestyles, shifts in consumer attitudes and opinions etc. However, Cameron (2012) specifies increasing level of customer resentment towards large amounts of profits made by pharmaceutical companies and sliding images of large pharmaceutical companies as the most significant social factor in the current environment. Technological factors include breakthroughs in pharmaceutical industry, issues associated with licensing and patenting drug manufacturing technology, as well as, the level of......

Words: 273 - Pages: 2

Premium Essay

Management Control Systems of Glaxosmithkline

...competitive advantage. Management controls are only one of the tools which managers use in implementing desired strategies. However strategies get implemented through management controls, organizational structure, human resources management and culture. In this paper we will discuss how management control system is implemented in various sectors of an pharmaceutical company ie. “GlaxoSmithKline Bangladesh Limited”. GlaxoSmithKline Bangladesh Limited carries with it an enviable image and reputation for the past 6 decades. A subsidiary of GlaxoSmithKline (GSK) is one of the world’s largest research-based pharmaceutical and healthcare companies GSK Bangladesh, continues to be committed to improving the quality of human life by enabling people to do more, feel better and live longer. The Company’s principle activities include secondary manufacture of pharmaceutical products and marketing of vaccines, pharmaceutical and healthcare products. GlaxoSmithKline Bangladesh Limited implements many control systems to attain their strategic objectives and competitive advantages. Some models that GlaxoSmithKline uses to make their activities and resources effective & efficient, for their employee performance evaluation and to enhance the overall performance of the organization will be discussed in this paper. Management Control Systems 1.1 Introduction: A management control systems (MCS) is a system which gathers and uses information to evaluate the performance......

Words: 4708 - Pages: 19

Premium Essay

Glaxosmithkline Found Guilty in Criminal Case

...Summary GlaxoSmithKline (GSK) is one of the main pharmaceutical and healthcare drug developer and manufacturer in the world. The product liability case with the British company, GSK includes the drugs Avandia, Paxil, Wellbutrin, and others (Thomas & Schmidt, 2012). The drug maker pleaded guilty and agreed to pay fines from the criminal charges in the case. GSK promoted its antidepressants for unapproved uses and failing to report safety data to the FDA on their diabetes drug. In addition, there are civil penalties within this case for improper marketing on six other drugs. The fines are the largest settlement within the pharmaceutical industry, totaling 3 billion (Thomas et al., 2012). There have not been any charges placed against personnel of GSK, at this time. However, GSK has agreed to withdraw bonuses from executives in their part of this illegal behavior. The claims in this case are improper practices during the 1990 to the mid 2000’s, came from former employees of GSK, which include the regional vice president and senior marketing manager (Thomas et al., 2012). The criminal and civil claims include the following: • Even though it was known the drug was linked to suicidal thoughts in teens, GSK promoted the use of Paxil to children. GSK misrepresented information on a clinical trial in a medical journal on the drug. • Wellbutrin was approved for depressive disorder; however, was promoted to use for off-label promotions of various products, “weight loss......

Words: 1317 - Pages: 6

Premium Essay

Case Study

...Case Study: GlaxoSmithKline, Bristol-Myers Squibb, and AIDS in Africa In this case study analysis paper, I shall argue that it is morally acceptable for Indian drug companies to copy and sell the AIDS drugs developed by GlaxoSmithKline and Bristol-Myers Squibb. The reasons and evidence that support this moral judgment are as follows: Utilitarianism states that an action is morally correct if the sum total benefits produced by the action is greater than the sum total of benefits produced by any other action that could have been performed in its place. In other words, does the action maximize benefits and minimize injuries to those affected by it? In this case study it’s known that AIDS is a major global problem, and by the Indian drug companies selling the drug developed by GlaxoSmithKline and Bristol-Myers Squibb would help the 28 million people infected with the disease in sub-Saharan Africa where the epidemic is at its worst and most of the individuals affected by it cannot afford the GlaxoSmithKline and Bristol-Myers Squibb made drugs. Since GlaxoSmithKline and Bristol-Myers Squibb will not provide a reasonably priced drug cocktail and the Indian drug companies will, the Indian drug companies will be able to save tens of thousands to hundreds of thousands (possibly even millions) of lives. Preserving life is the ultimate benefit that any action can produce. By preserving life many benefits subsequently follow. The individuals who will now live longer due to the......

Words: 2991 - Pages: 12

Premium Essay

Business Ethics Essay

...remembered when making a business decision, while others wrongly see them as an inconvenience. Earlier this year, the news was released that the American pharmaceutical company GlaxoSmithKline were fined $3 billion (£1.9 billion) after bribing doctors to increase their drugs sales. The company admitted corporate misconduct over the antidepressants named Paxil and Wellbutrin as well as the asthma drug Advair. They also admitted to encouraging the prescription of these unsuitable antidepressants to children. Not only was this extremely unethical but also unsafe. Thus, generating profit for the company but also danger for those who were inappropriately prescribed the drug. In order to permit such an action, any moral values which the company may have had must have been ignored. The company encouraged sales reps in the US to mis-sell three drugs to doctors as well as lavish hospitality and kickbacks on those who agreed to write extra prescriptions, including trips to resorts in Bermuda, Jamaica and California. Psychiatrists and their partners were flown to five-star hotels, on all-expenses-paid trips where speakers, paid up to $2,500 to attend, gave positive presentations on the drugs. They could enjoy diving, golf, fishing and other extra activities arranged by the company. GlaxoSmithKline also held eight luxurious three-day events in 2000 and 2001 at hotels in Puerto Rico, Hawaii and Palm Springs, California, to promote the drug to doctors for unapproved use. Those...

Words: 1108 - Pages: 5

Premium Essay

Accounting Gsk

...Executive Summary * The figures used for the ratio calculations were taken from the companies’ annual reports using the formulas shown in Exhibit 1. A. Global Pharmaceuticals and Medicine Manufacturing Industry (200 words) The global pharmaceutical and medicine manufacturing industry is one of the most profitable industries in the world. Currently, the industry has revenue of approximately $1.1 billion, with a forecast of growing at an annualised rate of 5.7% to $1.4 trillion by 2020. (Exhibit 4) Some of the reasons for this growth are the increasingly elderly population and rising middle class within emerging markets. Since the global population is aging, there has also been demand for products designed for age-related conditions. Lastly, the emergence of new viruses, pandemics and drug-resistant infections has prompted more research and development (R&D) in the industry, increasing the number of products in the pipeline Concentration in this industry is low, as the large pharmaceutical manufacturers only account for 15% of the market share. The most important issue faced by large pharmaceutical companies globally is the expiration of their patents, which results in the production of generic drugs by other manufacturers at lower price. The last 4 years companies have faced a series of simultaneous patent expiries, leading to severe sales losses of up to $250 billion from 2012 until today. Lastly, global trade and regulations have an impact on pricing......

Words: 3225 - Pages: 13

Premium Essay

Glaxo Kline Smith Ethica Issues

...GlaxoSmithKline Ethical Issues 2012 What happened (facts) GlaxoSmithKline (GSK) is one of the leading pharmaceutical companies in the world. They are based in London and they sell their products all over the world. Back in 2012 they were confronted with legal issues and plead guilty on 3 criminal counts. GSK paid a settlement of 3.5 billion dollars to support those charges. Unethical and illegal actions performed by GSK during that period ran from bribing doctors, to misreporting data from a trial and manipulating medical research data. Case Analysis (stakeholders) The stakeholders involved in this case were consumers, upper management, doctors and stockholders. Consumers were negatively affected because they were unconsciously taking ineffective and potentially life threatening medications. Upper management is directly responsible for the illegal actions. Some of the doctors who received bribes from GSK lost their medical license. Stockholders lost money because there was a negative impact on GSK reputation and stock. Model projection Information rights & obligations: On individual level they were unethical in withholding information and furnishing wrong information regarding their products. Society did not know this and this was against the law on political level. Accountability & Control: here it was a case of who should be held liable for unethical behavior affecting all the aforementioned stakeholders. In my opinion the upper management......

Words: 427 - Pages: 2

Premium Essay

Finance

... Function The purpose of a portfolio is to increase the wealth of the owner of the investments. Types There are many types of portfolios that contain investments such as stocks, bonds, mutual funds, commodities and real estate. Size If the value of most of the investments within a portfolio grows, the value of the entire portfolio will increase. Benefits A portfolio containing multiple investment types should lower the potential risk of loss. This diversification helps protect the entire portfolio from substantial losses when a single investment in the portfolio loses value. Companies Selected: Four companies from different sectors are selected to make portfolio. These are: 1. Nestle Pakistan Limited 2. Indus Motors 3. GlaxoSmithKline 4. Standered Chartered Bank Nestle Pakistan Limited: Nestle Pakistan is Pakistan’s one of the largest food company. It manufactures wide range of foods products in wellness, health, and nutrition sector. Nestle Pakistan offers the quality food with natural flavors. In fact, health and nutrition is more energetic than ever. Food has grown from being a need to becoming an expression of how we live. Nestlé Pakistan products are manufactured to give a healthy and safe source of diet to all family members. Nestlé has been serving Pakistani consumers since 1988, when the Switzerland-based Nestlé SA, first obtained a share in Milk pak Ltd. Indus Motors Company Limited: The......

Words: 1821 - Pages: 8

Premium Essay

Gsk Company Profile

...GlaxoSmithKline company profile Francis Weyzig Amsterdam, October 2004 Summary Business description GlaxoSmithKline (GSK) is one of the world’s largest research-based pharmaceutical corporations that discovers, develops, manufactures and markets branded human health products. Headquarters: UK, with additional operational headquarters in the USA Global presence: about 160 countries Primary markets: USA, France, Germany, UK, Italy and Japan Employees: approximately 103,000 GSK key figures for 2003 (in £ million) Sales 21,441 Materials and production costs 4,188 Marketing and administration 7,563 R&D expenditures 2,770 Operating income 6,920 Net profit 4,765 GSK has two main business divisions, pharmaceuticals and consumer healthcare. This profile deals with the pharmaceuticals division, which generates 85% of GSK’s sales. The five largest selling GSK products are Seretide/Advair for asthma and Chronic Obstructive Pulmonary Disease (COPD); Paxil/Seroxat and Wellbutrin, both antidepression drugs; Avandia/Avadamet for type 2 diabetes; and the antibiotic Augmentin. Each of these drugs generated above £800 million of sales in 2003. GSK produces a broad range of products of special importance to developing countries, including: Anti-malaria drugs Zentel (albendazole), for de-worming and the prevention of lymphatic filariasis Pentosam, against leishmaniasis Anti-retrovirals (ARVs) for the treatment of HIV/AIDS Tuberculosis drugs Vaccines for developing......

Words: 18642 - Pages: 75

Premium Essay

Business Research Ethics

...information to guide managerial decisions. Without proper research a business stands a chance of missed opportunities for growth, mismanaging funds, planning, and lowering the cost of goods. However, in more recent times there have been stories of unethical research that has taken place in society and rather than work toward managing a business for the better, we find that research was and has harmed companies and consumers involved. In 2007 and 2008 GlaxoSmithKilne was fined over $80,000 for the killing of 14 babies during an illegal lab research vaccine trial. Glaxo plead guilty and paid a criminal fine for misreporting data and failing to report adverse safety data from post marketing studies (Belkin), 2013). In July 2012, GlaxoSmithKline, also known as GSK, agreed to plead guilty and pay $3 billion to resolve the criminal and civil liabilities stemming from the unlawful promotion of prescription drugs. They failed to report safety data and falsified reporting practices. This is the largest health care settlement in the history of the United States. James M. Cole, Deputy Attorney General, is quotes as saying, “At every level, we are determined to stop practices that jeopardize patients’ health, harm taxpayers, and violate the public trust – and this historic action is a clear warning to any company that chooses to break the law” (US Fed News Service, pg. 1, paragraph 4, 2012). With the charges come strict requirements to increase accountability and......

Words: 835 - Pages: 4

Premium Essay

Finance

...de-licensing of the pharmaceutical industry, industrial licensing for most of the drugs and pharmaceutical products has been done away with. Manufacturers are free to produce any drug duly approved by the Drug Control Authority. Technologically strong and totally self-reliant, the pharmaceutical industry in India has low costs of production, low R&D costs, innovative scientific manpower, strength of national laboratories and an increasing balance of trade. The Pharmaceutical Industry, with its rich scientific talents and research capabilities, supported by Intellectual Property Protection regime is well set to take on the international market.  (b) Major competitors (Indian andGlobal): Indian Competitors 1. Aventis Pharma 2. GlaxoSmithKline 3....

Words: 1006 - Pages: 5

Premium Essay

Aleem

...History The history of the United Kingdom as a unified sovereign state began with the political union of the kingdoms of England, which included Wales, and Scotland. On the new kingdom, the historian Simon Schema said, "What began as a hostile merger would end in a full partnership in the most powerful going concern in the world... it was one of the most astonishing transformations in European history. A further Act of union in 1800 added the Kingdom of Ireland to create the United Kingdom of Great Britain and Ireland. Introduction: The United Kingdom (official name United Kingdom of Great Britain and Northern Ireland) consists of four countries united under one monarch and government. The countries are England, Scotland, Wales and Northern Ireland. Each have a distinct culture and feel of their own with some in Northern Ireland wishing to split from the United Kingdom and join the Republic of Ireland, with which the UK shares its only land border. England has traditionally been the dominant nation within the UK has over 80 percent of the share of the total population. People in Scotland and Wales have proud national traditions and languages. Scottish Gaelic is mainly spoken in the north west of the country, by a small proportion of the population. Welsh has a much bigger number of people speaking the language and all public signs in Wales are displayed in both Welsh and English. Economy Of Uk: Statistical Data Economy of the United Kingdom | Canary Wharf business......

Words: 3671 - Pages: 15

Premium Essay

The Top Five Global Pharma Companies Where They

...from 8 leading key opinion leaders, to produce an easy to read 25 page PowerPoint deck. Johnson & Johnson has reached a critical point in its product portfolio which should see the company convert from “cash cow” (high market share; low market growth) to “star” (high market share; high market growth) status by 2010. This is reflected in J&J having not less than 6 late stage drugs that will either unveil phase III data or be filed with the FDA within 2008 culminating in strong impact on its P&L account by 2010. Likewise the other cash cow Pfizer, boasts of at least 17 disclosed products under late phase development, with launches in the post-2010 period, thus are likely to buoy double digit sales growth beyond Lipitor patent expiry. GlaxoSmithKline on the other hand, has a product portfolio with a significant cash flow position this in turn has spurred on a meaningful gearing by GSK management. This puts the company firmly in a star performing position for 2008-2011. With asset consolidation of $23.5bn USD over three years post-2009, the company is likely to attain double-digit earnings growth out to 2011 with mid-digit growth in 2012 impacted by generic competition. In the...

Words: 1107 - Pages: 5

Premium Essay

Ravinder

...3 August 2011 2QCY11 Results Update | Sector: FMCG GlaxoSmithKline Consumer BSE SENSEX 17,941 Bloomberg Equity Shares (m) 52-Week Range (INR) 1,6,12 Rel. Perf. (%) M.Cap. (INR b) M.Cap. (USD b) S&P CNX 5,405 CMP:INR2,411 TP:INR2,300 Neutral SKB IN 42.1 2,525/1,739 2/26/37 101.5 2.3 Glaxo Smithkline Consumer Healthcare's (SKB) 2QCY11 adjusted PAT grew 15% YoY to INR825m (against our estimate of INR873m). Net sales grew ~22%, led by 16% volume growth. Biscuit volumes grew 49% and exports grew 57%. Input cost pressure drove a 300bp decline in gross margins and 34% higher ad spend led to a 150bp decline in EBITDA margins of 15.1%. SKB increased MFD prices by an average of 2.3% in July to recover some of the lost margins. Foodles grew just 13% (22% in 1HCY11). GSK launched Horlicks Gold at a 30% premium to the base Horlicks variant. New launches yet to make significant impact; Valuations rich for a single category business; Downgrade to Neutral We believe SKB is well placed to capture healthy growth in the MFD space and a strong rebound from 1QCY11 is testament to that. However, with competitive intensity increasing in this segment, SKB will have to continue to spend aggressively, which may reduce the frequency of new product introductions. Margin pressures are likely to persist and though we do not expect a severe gross margin contraction to continue, firm input costs and a changing product mix (rising share of low margin......

Words: 2867 - Pages: 12

Premium Essay

History

...follow, and we’ll e-mail you free updates as they’re published. You’ll receive free e-mail news updates each time a new story is published. You’re all set! Sign up Steven Nissen, a heart specialist at The Cleveland Clinic, has linked pharmaceutical drugs such as Vioxx and Avandia with high cardiovascular risks in patients. (Dustin Franz/FOR THE WASHINGTON POST) By Peter Whoriskey November 24, 2012 For drugmaker GlaxoSmithKline, the 17-page article in the New England Journal of Medicine represented a coup. The 2006 report described a trial that compared three diabetes drugs and concluded that Avandia, the company’s new drug, performed best. “We now have clear evidence from a large international study that the initial use of [Avandia] is more effective than standard therapies,” a senior vice president of GlaxoSmithKline, Lawson Macartney, said in a news release. What only careful readers of the article would have gleaned is the extent of the financial connections between the drugmaker and the research. The trial had been funded by GlaxoSmithKline, and each of the 11 authors had received money from the company. Four were employees and held company stock. The other seven were academic experts who had received grants or consultant fees from the firm. Whether these ties altered the report on Avandia may be impossible for readers to know. But while sorting through the data from more than 4,000 patients, the investigators missed hints of a danger that, when fully......

Words: 4274 - Pages: 18